توظيف الصحفيين

الناشرون وهيئات البث فرق تسويق المحتوى فرق العلاقات العامة والاتصال فرق المخاطر والاستخبارات ابحث عن صحفيين الرصد الإعلامي الأسعار

للصحفيين

وظائف صحفية أسعار الأجور أنشئ ملفك المجاني

نبذة عن Nicole

بخبرة 23 عامًا في الاتصالات الاستراتيجية، بنت Nicole مسيرة مهنية راسخة تميّزت بالالتزام والتعلّم المستمر. بدأت Nicole مسيرتها في The Janssen Pharmaceutical Companies of Johnson & Johnson، حيث أمضت العقد الأول في صقل مهاراتها في التواصل الداخلي والخارجي، وبناء العلامة التجارية للشركة، واستراتيجية المحتوى والتسويق، والاتصالات في المجالات العلاجية، والعلاقات العامة، والحملات، ووسائل التواصل الاجتماعي. متخصصة في R&D Communications، تولّت Nicole مسؤوليات على الصعيد البلجيكي والأوروبي ولاحقًا العالمي. أحد المشاريع البارزة ‘From Molecule to Medicine’ تحت قيادتها نال ثلاث جوائز مرموقة: the World Double Gold Medal at the New York Festivals و the Global Awards for the World's Best Work in Healthcare Communications. هذا الإنجاز أبرز قدرة Nicole على قيادة مبادرات ذات أثر. طوّرت Nicole أيضًا برامج لإشراك وتثقيف كل من الموظفين الداخليين وأصحاب المصلحة الخارجيين، مما يعكس التزامها بتعزيز التواصل الفعّال داخل المؤسسات. بعد عشر سنوات، أسّست Nicole وكالتها الخاصة في الاتصالات، وبنت محفظة عملاء متنوعة تتراوح من شركات ناشئة إلى شركات متعددة الجنسيات. وعلى الرغم من أن الوكالة ركّزت أساسًا على قطاعي الرعاية الصحية والعلوم الحياتية، فقد خدمت أيضًا عملاء في قطاعات تكنولوجيا المعلومات والموارد البشرية والاستشارات. أدت خبرة الوكالة في إنتاج المحتوى الإبداعي والحملات إلى مشاريع ناجحة عبر بلجيكا وأوروبا والولايات المتحدة. منذ بداية COVID-19، عملت Nicole بشكل أساسي كخبيرة اتصالات مستقلة. إلى جانب عملها الحر في الاتصالات، تتابع Nicole شغفها بالصحافة كمراسلة صحية مستقلة لبلجيكا لدى Euractiv (Mediahuis). يتيح لها هذا الدور البقاء على تواصل عميق مع الاتجاهات الراهنة في الرعاية الصحية، مما يمزج بين خبرتها في الاتصالات الاستراتيجية والتفاني في صحافة مفيدة وذات أثر jou

اللغات
الهولندية الإنجليزية الفرنسية الألمانية
ظهر في
Rapporteur Euractiv

الأعمال 13

'Recipe to be dead-last': MEPs push to make biotech’s SPC reward count

Rapporteur 9 أكتوبر 2026 English

MEPs backing the EU Biotech Act argue that an additional year of supplementary protection for a narrowly defined group of biotech medicines could encourage European research, manufacturing and patient access. Eligibility would require a new active substance, distinct and sufficiently safe and effective treatment, clinical trials in more than two EU member states, and at least one manufacturing step in the Union. Stine Bosse proposes early SPC candidate status linked to the European Medicines Agency’s PRIME scheme, a longer extension for orphan drugs and industry contributions to public-health infrastructure; Wouter Beke warns that overly strict conditions could undermine the incentive. Public payers and health technology assessment bodies warn of higher costs, while industry-backed modelling describes the budget impact as negligible. Committee votes are expected in December and a plenary vote around the turn of the year; trilogue negotiations are unlikely before 2027.

Biotechnology Pharmaceuticals Supplementary Protection Certificates European Union legislation Drug pricing and healthcare costs Clinical trials European Union Belgium Denmark European Parliament European Commission European Medicines Agency
أسلوب التغطيةإخباري

Mostly factual reporting, with attributed advocacy and competing arguments from MEPs and industry and public-payer stakeholders.

A Decade On, the Evidence Is In: What Biosimilar Treatment Means for Patients

Rapporteur 6 أكتوبر 2026 English

A decade of biosimilar use in Europe has expanded access to biologic treatment for rheumatoid arthritis and related conditions, while evidence indicates patients switching to biosimilars generally maintain comparable effectiveness and safety. Studies report stable or improved outcomes, and regulators cite safety data covering one million patient-treatment years. Biosimilars have increased treatment use and generated substantial savings, but access remains markedly unequal: Eastern European patients receive far fewer treatment days with TNF-alpha inhibitors and biosimilars than patients elsewhere. Patient anxiety about switching remains important, making clear communication and reassurance essential.

Biosimilars Rheumatoid Arthritis Patient Access to Medicines Biologic Drugs European Healthcare Europe Eastern Europe United Kingdom European Medicines Agency World Health Organization National Rheumatoid Arthritis Society Newcastle Health Research Partnership
أسلوب التغطيةإخباري

Evidence-led reporting with a favorable framing of biosimilars and their impact on patient access.

Belgium needs cardiovascular plan by summer 2027, says cardiology head

Rapporteur 15 سبتمبر 2026 English

Belgium should establish a national cardiovascular plan by summer 2027, according to cardiologist Rik Willems, who says an intergovernmental working group has begun discussions. The Belgian Society of Cardiology and Belgian Heart League propose embedding routine blood-pressure, cholesterol and blood-sugar checks in general practice, supported by a chosen risk score and electronic health records. Fragmented federal and regional responsibilities, limited disease and care-quality data, and misconceptions that cardiovascular disease affects only older people or results solely from personal choices are key barriers. Willems calls for political coordination, stronger data systems and teamwork across healthcare professions.

Cardiovascular Health Preventive Health Screening Belgian Health Policy Electronic Health Records Belgium European Union Belgian Society of Cardiology Belgian Heart League European Commission Belgian government European Society of Cardiology Rik Willems
أسلوب التغطيةإخباري

Primarily a factual interview, with some advocacy for coordinated prevention and improved cardiovascular care.

السياق السياسيوسط

Focuses on public health coordination and policy implementation without advocating a partisan ideological position.

Only EU-based drugmaker in Trump's pricing deal keeps Europe guessing on cost

Rapporteur 11 سبتمبر 2026 English

UCB, the only EU-headquartered company among nine drugmakers signing Donald Trump's most-favoured-nation pricing agreement, has pledged a more balanced approach to future medicine launches across developed markets, participation in a U.S. Medicaid pricing scheme, and continued U.S. manufacturing investment. In exchange, it will avoid pharmaceutical tariffs and future pricing mandates, though the specific terms remain confidential. Its planned $2 billion Georgia facility is projected to generate about $5 billion in U.S. economic impact and more than 330 permanent jobs. UCB says the plant complements rather than replaces global operations and points to roughly €300 million in previously announced Belgian projects, while offering no amount for future investment in Europe. The company did not clarify whether its commitments could mean higher prices for new medicines in European markets. The impact will become clearer when UCB next seeks European payer coverage for a new medicine.

Drug pricing Pharmaceutical manufacturing U.S.-EU economic relations Investment in biotechnology United States Belgium European Union White House U.S. Department of Health and Human Services U.S. Department of Commerce State of Georgia Rowen Foundation
أسلوب التغطيةإخباري

Mostly factual reporting, with some framing around the unanswered question of how the deal may affect European medicine prices.

AstraZeneca Belgium chief warns Europe’s drug access problem is undermining clinical research

Rapporteur 10 سبتمبر 2026 English

Angela Thompson, AstraZeneca’s Belgium and Luxembourg president, says the company’s clinical-trial investment in Belgium has fallen by about 20% since 2024, citing slow European trial approvals and limited reimbursement of medicines. She argues that low access to approved medicines makes Belgium less attractive for trials, putting jobs, early patient access, and future investment at risk. Thompson urges governments to treat healthcare spending as a long-term economic investment and says stronger patent protection and reliable reimbursement are both needed to support pharmaceutical research. She also criticizes proposed eligibility rules for extending supplementary protection certificates as too restrictive, and warns that companies may direct investment elsewhere if Europe’s policy environment does not improve.

Pharmaceutical Industry Clinical Trials Medicine Reimbursement Healthcare Investment Drug Access Belgium Europe United States European Medicines Agency European Union China Angela Thompson
أسلوب التغطيةمتوازن

Interview presents factual context alongside AstraZeneca’s executive arguing for increased healthcare investment, reimbursement, and stronger medicine protections.

New Alzheimer's drugs: what the next treatment wave could mean for patients

Rapporteur 9 سبتمبر 2026 English

Disease-modifying Alzheimer's drugs have begun reaching European patients, but treatment depends on early, biomarker-confirmed diagnosis and access remains uneven; in the Czech Republic, initial patients must pay out of pocket. EU-approved lecanemab and donanemab require infusions and MRI monitoring because of the risk of brain swelling or bleeding. Research is expanding beyond amyloid toward tau, inflammation and immune targets, while newer delivery methods such as injectable lecanemab and trontinemab may reduce treatment burdens. A US-cleared p-tau217 blood test could make diagnosis easier, and researchers are also testing lifestyle-based care and prevention in people without symptoms.

Alzheimer's disease Alzheimer's drug development Early diagnosis Biomarker testing Access to treatment Czech Republic European Union United States European Commission Czech Brain Aging Study Mayo Clinic Study of Aging Katerina Sheardova
أسلوب التغطيةإخباري

Primarily factual reporting, with limited evaluative framing and attributed opinions from researchers.

Europe Has Plans for Cancer and Heart Disease—Lung Health Is Still Waiting

Rapporteur 8 سبتمبر 2026 English

The European Union has dedicated plans for cancer and cardiovascular disease but no comprehensive lung-health strategy, despite the substantial burden of COPD and asthma. Patient and clinician groups are urging the EU to consolidate fragmented initiatives into a European Lung Health Plan, backed by coordinated prevention, earlier diagnosis, and long-term disease management. The article argues that better respiratory care could reduce avoidable hospital admissions and costs, strengthen strained health systems, improve patient outcomes, and lower healthcare emissions. It identifies the EU’s next long-term budget, beginning in 2028, as a key opportunity to fund coordinated action.

Respiratory Health Chronic Obstructive Pulmonary Disease Asthma European Union Health Policy Healthcare Sustainability Climate Change and Health European Union United Kingdom European Lung Health Group MEP Lung Health Group World Health Organization Organisation for Economic Co-operation and Development
أسلوب التغطيةتفسيري

Advocates for a European lung-health plan, using evidence and persuasive language to argue for coordinated policy action.

السياق السياسيوسط

Policy advocacy focused on public health, prevention, and healthcare sustainability rather than a partisan political position.

Locked Out of EU Science, Hungary Falls Behind on Alzheimer’s

Rapporteur 2 سبتمبر 2026 English

Hungary’s exclusion from EU research programmes has disrupted university collaboration and is worsening the country’s ability to keep pace with advances in Alzheimer’s diagnosis and treatment. Although a late-May 2026 agreement began restoring some frozen funds, Horizon Europe access remains blocked while changes to university trusts are pending. A survey found substantial effects on early-career researchers, including plans to seek work abroad and greater difficulty maintaining international partnerships. Hungary also lacks a national dementia plan and adequate diagnostic infrastructure: only about 1% of an estimated 250,000 people with dementia have a biological diagnosis, limiting access to treatments intended for early Alzheimer’s. Andras Horvath calls for national testing standards, a dementia research fund and registry, a coordinated diagnostic pathway, and—above all—Hungary’s reintegration into European research programmes.

Alzheimer’s Disease Dementia Research EU Research Funding Healthcare in Hungary Medical Diagnosis Hungary European Union Budapest European Commission Horizon Europe Erasmus+ Court of Justice of the European Union
أسلوب التغطيةمتوازن

Primarily reported information and attributed expert views, with some evaluative framing about Hungary’s research and diagnostic gaps.

The Biosimilar Void: Why Europe’s Next Decade of Drug Savings Is Not Guaranteed

Rapporteur 25 أغسطس 2026 English

Europe faces a projected shortfall in biosimilar competition as many biologic medicines lose exclusivity over the next decade. IQVIA estimates that missing development pipelines could forgo at least €15 billion in savings, with losses potentially much higher. The article attributes weak manufacturer participation to aggressive price erosion, single-winner tenders, international reference pricing, and additional cost-recovery measures. It argues that multi-winner procurement, incentives for prescribing and switching, and recognition of quality and supply reliability could sustain competition. Proposed opportunities include streamlined European Medicines Agency guidelines and a revision of EU procurement rules; policy choices will determine whether the next wave of patent expiries brings continued savings and access.

Biosimilars European Healthcare Drug Pricing and Procurement Medicine Access Pharmaceutical Market Competition Europe European Union Norway Medicines for Europe European Medicines Agency Adam Levysohn Samsung Bioepis
أسلوب التغطيةتفسيري

Primarily evidence-led analysis, but it advances a clear policy argument for pro-competition procurement and sustainable market incentives.

السياق السياسيوسط

Focuses on pharmaceutical procurement and healthcare policy, advocating competition and sustainability without a broader partisan position.

Belgium's medicine price cuts risk its own innovation, economist warns

Rapporteur 25 أغسطس 2026 English

Economist Walter Van Dyck argues that Belgium's aggressive medicine price reductions and delayed reimbursement may protect budgets in the short term but risk weakening pharmaceutical innovation and slowing patient access. With Paola Argiolas, he proposes reforming the clawback so overspending is attributed and balanced across years, preserving a price gap between branded and generic medicines and directing savings to innovation, paying for new medicines early with later price settlements, and creating a European fund for costly advanced therapies. He also warns that US Most-Favoured-Nation pricing could push European prices upward and delay access, while noting that joint European purchasing can reduce costs but pricing remains a national responsibility.

Pharmaceutical Pricing Medicine Access and Reimbursement Pharmaceutical Innovation European Health Policy Belgium European Union United States Belgian government European Commission Beneluxa Vlerick Business School Walter Van Dyck
أسلوب التغطيةتفسيري

Interview-led argument advances policy recommendations and critiques Belgium's pricing approach, while including factual context.

السياق السياسيوسط

Policy-focused discussion of pharmaceutical pricing and health-system design; it does not clearly align with a partisan ideology.

اعرض الأعمال كلها (13) بحساب مجاني

وظّف رسالة
×

سجّل لمراسلة Nicole

هل لديك حساب بالفعل؟ تسجيل الدخول
هل تبحث عن عمل؟ سجّل كصحفي
وثّق بريدك الإلكتروني لإتمام التسجيل
لقد أرسلنا للتوّ رسالة إلكترونية إلى . يرجى التحقّق من صندوق الوارد والنقر على الرابط لتوثيق عنوان بريدك الإلكتروني وإتمام تسجيلك. وإذا لم تجد الرسالة، فتأكّد من التحقّق من مجلد البريد العشوائي أو غير المرغوب فيه.
لم تستلم البريد الإلكتروني؟

سجّل للاطّلاع على الملفات الشخصية

هل لديك حساب بالفعل؟ تسجيل الدخول
هل تبحث عن عمل؟ سجّل كصحفي
وثّق بريدك الإلكتروني لإتمام التسجيل
لقد أرسلنا للتوّ رسالة إلكترونية إلى . يرجى التحقّق من صندوق الوارد والنقر على الرابط لتوثيق عنوان بريدك الإلكتروني وإتمام تسجيلك. وإذا لم تجد الرسالة، فتأكّد من التحقّق من مجلد البريد العشوائي أو غير المرغوب فيه.
لم تستلم البريد الإلكتروني؟